Compound 1 Benzoxazole Derivative TTR Stabilization Dosing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for abnormal transthyretin (TTR) aggregation and fibril formation in amyloidosis have shown limited effectiveness, with no appreciable change in mortality rates for TTR amyloid cardiomyopathy over several decades, as indicated by retrospective reviews from major clinical centers.

Innovation Solution

Administration of Compound 1, a benzoxazole derivative, in therapeutically effective amounts ranging from 50 mg to 2,000 mg daily, either as a single dose or in divided doses, to stabilize the tetrameric form of TTR and inhibit amyloid formation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If tafamidis is administered to treat TTR amyloidosis, then TTR aggregation and fibril formation is inhibited, but treatment effectiveness remains limited with no appreciable change in mortality rates

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidmortality rate improvement

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent applies parameter changes by modifying the chemical structure of tafamidis to create Compound 1 with improved pharmacological properties. Specifically, the patent optimizes the benzoxazole derivative structure by adjusting substituents and molecular weight to enhance TTR binding affinity and stability, thereby improving treatment effectiveness and potentially reducing mortality rates in TTR amyloidosis patients

Inventive Principle:

Principle #35Parameter changes

2Stability of the object's composition

If higher doses of Compound 1 are administered, then TTR stabilization and amyloid formation inhibition is enhanced, but dosage complexity and potential side effects increase

Engineering Contradiction:

ImproveTTR stabilizationVSAvoiddosage regimen complexity

Core Design Contradiction:

Stability of the object's compositionVSDevice complexity

Solution Approach 1:

The patent applies preliminary action by establishing optimal dosing regimens in advance through preclinical and clinical studies. The patent specifies predetermined dosage ranges (50-2000 mg daily) and administration schedules that have been optimized to achieve effective TTR stabilization while minimizing complexity and potential side effects, allowing clinicians to implement treatment without needing to adjust doses during therapy

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Compound 1 effectively maintains a desired trough blood plasma concentration, leading to significant stabilization of TTR, reduction in amyloid fibril formation, and clinical improvements in patients with TTR amyloidosis, including improved heart function and quality of life measures.

Implementation Method 1

stabilizing the tetrameric form of TTR inhibits the misfolding of amyloidogenic monomers and subsequent TTR amyloid formation and deposition

Methodology Applied

Scientific EffectProtein stabilization:

Implementation Method 2

targeting protein protein interactions (PPIs) is of therapeutic interest

Methodology Applied

Scientific EffectMolecular binding:

Data Source

PatentUS20250041276A1Methods of treating TTR amyloidosis using AG10

Publication Date: 2025.02.06 EIDOS THERAPEUTICS INC

AI summary

Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects.